Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform.
Flash Therapeutics has raised $17.6M in total funding. The most recent round was Debt Financing. The last funding was announced in August 2021.
Flash Therapeutics's investors include Elaia, Auriga Partners, Galia Gestion, Techlife Capital, Alain Sainsot.
Flash Therapeutics is headquartered in Toulouse, France.
Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform.
Flash Therapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Flash Therapeutics — Funding & Investors." VCBacked, August 7, 2021, https://www.vcbacked.co/company/flash-therapeutics. Accessed September 29, 2026.
VCBacked. (2021). Flash Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/flash-therapeutics
{{cite web |title=Flash Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/flash-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated